Interim report
Page 1
Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India |Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com October 29, 2026 National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051, Maharashtra. Symbol: STAR BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001, Maharashtra. Scrip Code: 532531 Dear Madam/ Sir, Sub: Outcome of Board Meeting of the Company held on October 29, 2026 Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) We are pleased to enclose the Unaudited Financial Results (Consolidated and Standalone) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and half year ended September 30, 2026, as approved by the Board of Directors of the Company at their meeting held today i.e., October 29, 2026. Board Meeting commenced at 16:45 hrs (IST) and concluded at 18:15 hrs IST. The above information shall be made available on the website of the Company at www.strides.com. This is for your information and records. Thanks & Regards, For Strides Pharma Science Limited, Manjula Ramamurthy Company Secretary & Compliance Officer ICSI Membership No.: A30515 Encl. as above 8 Strides
Page 2
B S R & Co. LLP Chartered Accountants Embassy Golf Links Business Park Pebble Beach, B Block, 3rd Floor No. 13/2, off Intermediate Ring Road Bengaluru - 560 071, India Telephone: +91 80 4682 3000 Fax: +91 80 4682 3999 Registered Office: B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 4 Limited Review Report on unaudited consolidated financial results of Strides Pharma Science Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Strides Pharma Science Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Strides Pharma Science Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its associates and joint venture for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure I of this limited review report. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Page 3
B S R & Co. LLP Limited Review Report (Continued) Strides Pharma Science Limited Page 2 of 4 6. We did not review the interim financial information of 2 Subsidiaries included in the Statement, whose interim financial information reflects total assets (before consolidation adjustments) of Rs. 6,861 million as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 2,224 million and Rs. 4,414 million, total net profit after tax (before consolidation adjustments) of Rs. 76 million and Rs. 429 million and total comprehensive income (before consolidation adjustments) of Rs. 76 million and Rs. 429 million, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, and cash outflows (net) (before consolidation adjustments) of Rs. 167 million for the period from 1 April 2026 to 30 September 2026. as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent’s management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter. 7. The Statement includes the interim financial information of 25 Subsidiaries which have not been reviewed, whose interim financial information reflect total assets (before consolidation adjustments) of Rs. 49,386 million as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 1,668 million and Rs. 3,661 million, total net loss after tax (before consolidation adjustments) of Rs. 244 million and Rs. 172 million and total comprehensive loss (before consolidation adjustments) of Rs. 460 million and Rs. 146 million, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash outflows (net) (before consolidation adjustments) of Rs. 325 million for the period from 01 April 2026 to 30 September 2026. as considered in the Statement. The Statement also includes the Group’s share of net profit/(loss) after tax of Rs. 9 million and Rs. (4 million) and total comprehensive income/(loss) of Rs. 9 million and Rs. (4 million), for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively as considered in the Statement, in respect of 4 associates and a joint venture, based on their interim financial information which have not been reviewed. According to the information and explanations given to us by the Parent’s management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of this matter. For B S R & Co. LLP Chartered Accountants Firm’s Registration No.:101248W/W-100022 G Prakash Partner Bangalore Membership No.: 099696 29 October 2026 UDIN:26099696LPDUPC3899 G PRAKA SH Digitally signed byG PRAKASH Date: 2026.10.29 17:23:10 +05'30'
Page 4
B S R & Co. LLP Limited Review Report (Continued) Strides Pharma Science Limited Page 3 of 4 Annexure I List of entities included in unaudited consolidated financial results. Sl. No Name of component Relationship 1 Amexel Pte. Ltd, Singapore Subsidiary 2 Aponia Laboratories Inc., United States Associate 3 Arco Lab Private Limited, India Subsidiary 4 Asaco Trinity Proprietary Limited, South Africa Associate (Associate w.e.f 22 May 2026) 5 Beltapharm S.R.L, Italy Subsidiary 6 Fairmed Healthcare GmbH, Germany Subsidiary 7 Neviton Softech Private Limited, India Subsidiary 8 Neviton Technologies Inc., USA Subsidiary 9 Pharmapar Inc., Canada Subsidiary 10 Pivot Path Private Limited Associate (Subsidiary till 30 June 2026) 11 Sihuan Strides (HK) Ltd., Hong Kong Joint venture 12 Strides Arcolab International Ltd, United Kingdom Subsidiary 13 Strides Consumer LLC (USA) Subsidiary 14 Strides Consumer Private Limited, India Subsidiary 15 Strides Foundation Trust, India Trust 16 Strides Global Consumer Healthcare Limited, UK Subsidiary 17 Strides Lifesciences Limited, Nigeria Subsidiary 18 Strides Netherlands B.V., Netherlands Subsidiary 19 Strides Nordic ApS, Denmark Subsidiary
Page 5
B S R & Co. LLP Limited Review Report (Continued) Strides Pharma Science Limited Page 4 of 4 20 Strides Pharma (Cyprus) Limited, Cyrpus Subsidiary 21 Strides Pharma Asia Pte. Ltd., Singapore Subsidiary 22 Strides Pharma Canada Inc., Canada Subsidiary 23 Strides Pharma Global (UK) Ltd, United Kingdom Subsidiary 24 Strides Pharma Global Pte. Limited, Singapore Subsidiary 25 Strides Pharma Inc., USA Subsidiary 26 Strides Pharma International AG, Switzerland (formerly, Fairmed Healthcare AG, Switzerland) Subsidiary 27 Strides Pharma International Limited, Cyprus Subsidiary 28 Strides Pharma New Zealand Pty Limited Subsidiary 29 Strides Pharma SA Pty Ltd, South Africa Subsidiary 30 Strides Pharma Science Limited, India Holding 31 Strides Pharma Science Pty Ltd, Australia Subsidiary 32 Strides Pharma UK Ltd, United Kingdom Subsidiary 33 SVADS Holdings SA, Switzerland Subsidiary 34 Trinity Pharma (Pty) Ltd, South Africa Subsidiary 35 UCL Brands Limited, Kenya Subsidiary 36 Universal Corporation Limited, Kenya Associate 37 Vensun Pharmaceuticals, Inc., United States Subsidiary
Page 6
STRIDES PHARMA SCIENCE LIMITED 8 Strides CIN: L24230MH1990PLC057062 Regd. Office : Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashl, Navl Mumbai - 400 703 Corp. Office: "Strides House", Bilekahalli , Bannerghatta Road , Bangalore-560 076. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Rs. In MIiiion SI. Particulars 3Months Preceding 3 Corresponding 3 Year Iodate Year to dale Previous year No. ended Months Months ended In figures tor the figures for the ended September 30, ended the previous period ended previous period March 31, 2026 2026 June 30, 2026 year September 30, ended September September 30, 2026 30, 2025 2025 UNAUDITED UNAUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED (1) (2) (3) (4) (5) (6) Continuing operations I Revenue from ope rations 14,297.34 12,654.07 12,208.31 26,951.41 23,405.67 48,586.83 II Other income (Refer Nole 7) 40.83 48.90 271.40 89.73 357.23 1,507.13 Ill Total Income (I + II) 14,338.17 12 ,702.97 12,479.71 27,041.14 23,762 .90 50,093.96 IV Expenses (a) Cost of materials consumed 5,649.47 4,147.15 4,297.56 9,796.62 6,903.36 15,589.19 (b) Purchases of stock-in-trade 1,809.73 1,663.81 418.00 3,473.54 1,627.13 3,615.36 (c) Changes in inventories of finished goods , work-in-progress and stock-in-trade (1 ,164.92) (859.08) 437.05 (2,024.00) 1,064.95 382.75 (d) Employee benefits expense 2,382.74 2,429.86 2,267.81 4,812.60 4,522.99 9,289.57 (e) Finance costs 465.41 405.61 461.27 871.02 935.87 1,785.45 (f) Depreciation and amortisation expense 572.15 563.99 496.43 1,136.14 985.29 2,024.01 (g) Other expenses 3,111.18 2,974.59 2,472.22 6,085.77 4,790.83 10,457.03 Total expenses (IV) 12,825.76 11,325.93 10,850.34 24,151.69 20,830 .42 43,143 .36 V Profit belore exceptional Items and tax (Ill - IV) 1,512.41 1,377.04 1,629.37 2,889.45 2,932.48 6,950.60 VI Exceptional items (Refer note 4) (17.04) 631.97 (87.72) 614.93 (171.39) (268.43) VII Profit before tax (V + VI) 1,495.37 2,009.01 1,541.65 3,504.38 2,761.09 6,682.17 VIII Share of profil/(loss) of joint venture and associates , net of taxes - (net) 8.99 (12.85) (10.48) (3.86) (9.49) 4.69 IX Profit before tax (VII + VIII) 1,504.36 1,996.16 1,531.17 3,500.52 2,751.60 6,686.86 X Tax expense - Current lax 216.79 290.06 227.39 506.85 336.19 778.76 - Deferred lax (53.61) 51.17 (11.46) (2.44) 44.24 162.90 Total tax expense (X) 163.18 341.23 215.93 504.41 380.43 941.66 XI Profit for the period/year (IX - X) 1,341.18 1,654.93 1,315.24 2,996.11 2,371.17 5,745.20
Page 7
STRIDES PHARMA SCIENCE LIMITED 8 Strides CIN: L24230MH l 990PLC057062 Regd. Office : Cyber One. Unit No. 902, Plot No • 4 & 6, Sector 30A. Vashl. Navl Mumbai • 400 703 Corp . Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 07 6. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Rs. In MIiiion SI. Particulars 3Monlhs Preceding 3 Corresponding 3 Year Iodate Year Iodate Previous year No. ended Months Months ended In figures tor the figures for the ended September 30, ended the previous period ended previous period March 31, 2026 2026 June 30, 2026 year September 30, ended September September 30, 2026 30, 2025 2025 UNAUDITED UNAUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED (1) (2) (3) (4) (5) (6) XII Other comprehensive Income A (ii Items that will not be reclassified to statement of profit and loss (274.01) 322.53 (657.98) 48.52 162.06 (467.01) (ii) Income tax relating to items that will not be reclassified to statement of profit and loss 58.44 (80.81) 165.50 (22.37) (40.82) 91.12 B (i) Items that may be reclassified to statement of profit and loss 645.13 125.67 144.50 770.80 (115.03) 615.31 (ii) Income tax relating to items that may be reclassified to statement of profit and loss (37.97) (78.22) 105.48 (116.19) 138.18 200.81 Total other comprehensive Income tor the period/year (XII) 391.59 289.17 (242.50) 680.76 144.39 440.23 XIII Total comprehensive Income tor the period/year (XI + XII) 1,732.77 1,944.10 1,072.74 3,676.87 2,515.56 6,185.43 Prolll for the period/year attributable lo: - Owners of the Company 1,308.36 1,569.14 1,275.34 2,877.50 2,271.42 5,561.93 - Non-controlling interests 32.82 85.79 39.90 118.61 99.75 183.27 1,341.18 1,654.93 1,315.24 2,996.11 2,371.17 5,745.20 Other comprehensive Income tor the period/year - Owners of the Company 385.46 281.83 (252.10) 667.29 131.80 415.09 - Non-controlling interests 6.13 7.34 9.60 13.47 12.59 25.14 391.59 289.17 (242.50) 680.76 144.39 440.23 Total comprehensive Income tor the period/year - Owners of the Company 1,693.82 1,850.97 1,023.24 3,544.79 2,403.22 5,977.02 - Non-controlling interests 38.95 93.13 49.50 132.08 112.34 208.41 1,732.77 1,944.10 1,072.74 3,676.87 2,515.56 6,185.43 Earnings per equity share (face value of Rs. 10/· each) (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) (l) Basic (in Rs.) 14.19 17.02 13.84 31.22 24.64 60.34 (2) Diluted (in Rs.) 14.19 17.02 13.84 31.22 24.64 60.34 See accompanying notes lo the Financial Results
Page 8
STRIDES PHARMA SCIENCE LIMITED 8 Strides A ASSETS I Non-current assets (a) Property, plant and equipment (bl Capital work-in-progress (c) Righi -of -use assets (di Investment property (e) Goodwill (fl Other Intangible assets (g) Intangibles assets under development (hi Investment in associates and joint ventures (ii Rnancial assets (ii Investments (ii) Other financial assets Iii Deferred tax assets (net) (kl Income tax assets (net) (I) Other non-current assets Total non-current assets II Current assets (a) Inventories (bl Financial assets Iii Trade receivables (ii) Cash and cash equivalents (iii) Other balances with banks (iv) Loans (vi Other financial assets (c) Other current assets Total current assets Assets held for sale Total Assets CIN: L24230MH 1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashl, Navl Mumbai - 400 703 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 07 6. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 CONSOLIDATED BALANCE SHEET Rs. In Mllllon Particulars As al Asal September 30, March 31, 2026 2026 UNAUDITED AUDITED 9,103.67 9,141.97 2,263.10 1,611.23 478.61 782.33 2.14 2.43 6,007 .12 5,944 .24 5,349 .56 5,134 .95 3,118 .66 2,861.58 582.67 124.74 2,877.96 2,788.82 1,155.23 1,090.60 2,694.52 2,838.62 223.23 470.10 660.05 347.32 34 516.52 33138 .93 18,734.73 16,347.94 14,639.62 12,889.64 1,373.35 1,886.96 101.46 244.46 79.85 81.36 1,629.57 1,972.09 3 813 .06 2 705.48 40 371.64 36 127.93 - 5.46 74888.16 69 272.32
Page 9
STRIDES PHARMA SCIENCE LIMITED 8 Strides B EQUITY AND LIABILITIES I Equity (a) Equity share capital (b) Other equity Equity attributable lo owners of the Company Non- Controlling interests Total equity II Liabilities 1 Non-current liabilities (a) Financials liabilities (i) Borrowings - Borrowings US revolver facility - Borrowings others (ii) Lease Liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred lax liabilities (net) Total non-current liabilities 2 Current liabilities (a) Financials liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables CIN: L24230MH l 990PLC057062 Regd . Office: Cyber One, Unit No. 902, Plot No • 4 & 6, Sector 30A, Vashl, Navl Mumbai • 400 703 Corp. Office: "Strides House", Bilekahalli , Bannerghatta Road, Bangalore-560 076. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 CONSOLIDATED BALANCE SHEET Particulars Rs. In Mllllon As at Asal September 30, March 31, 2026 2026 UNAUDITED AUDITED 921.73 33,243.00 34,164.73 540.25 34,704 .98 2,634.27 3,025.75 302.81 363.96 1,153.87 1,352.73 8,833 .39 12,811.21 274.64 921.73 30,153.92 31,075.65 417.72 31,493.37 3,010.50 2,512.66 518.40 312.13 1,263.64 1,206.69 8,824.02 l l,163.74 374.53 (a) total outstanding dues of micro enterprises and small enterprises and 870.98 464.0l (b) total outstanding dues of creditors other than micro enterprises and small enterprises (iv) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current tax liabilities (net) Total current llabllltles Total Liabilities Total Equity and Habllllles 13,456.24 12,632.79 1,285.45 2,122.79 1,382.42 749.53 950.78 963.59 318.07 483.95 31,349 .79 28,954.93 40,183 .18 37,778.95 74,888.16 69,272.32 .
Page 10
STRIDES PHARMA SCIENCE LIMITED 8 Strides CIN: L24230MH 1990PLC057062 Regd. Offlce: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashl, Navl Mumbai - 400 703 Corp. Office : "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30 2026 CONSOLIDATED STATEMENT OF CASH FLOW Rs. In MIiiion SI. Particulars For the half year For the previous half For the previous year No. ended year ended ended September 30, 2026 September 30, 2025 March 31, 2026 UNAUDITED UNAUDITED AUDITED A. Cash flow from operating activities Profit/ (loss) before tax from: Continuing operations 3,500.52 2,751.60 6,686.86 3,500.52 2,751 .60 6,686.86 Adjustments for: - Depreciation and amortisation expense 1,136.14 985.29 2,024.01 - Share of (profit}/loss of joint ventures and associates 3.86 9.49 (4.69} - Gain/(loss} on sale of property, plant and equipment, other intangible assets and investment property (net} 22.59 (6.16} (1,042.40} - Share based compensation expense 0.88 1.68 3.14 - Business combination and restructuring expenses - 2.89 4.62 - Interest expense on borrowings & others 871.02 935.87 1,785.45 - Interest and dividend income (79.92} (325.31} (404.81} - Rental income (3.83} (11.06} (12.69} - Liability / provision no longer required written back (0.07} - (0.09} - Loss allowance on trade receivables (30.61} 3.97 (63.09} - Movement in inventory obsolescence 687.15 - 173.28 - Impairment and write down of assets - (0.01} 34.70 - Gain on loss of control in subsidiary (742.07} - - - Derecogntion of ROU asset and liability - (9.25} (35.15} - Unrealised exchanae aain / floss} lnetl 1315.071 1484.0ll 1408.341 Operating profit before working capital changes 5,050.59 3,854.99 8,740.80 Changes ln working capital : Decrease / (Increase} in trade and other receivables (2,861.83} 362.96 (1,093.24} Increase in inventories (2,803.47} (1,493.58} (3,018.48} Decrease in trade and other n.-.vables 2 005.14 1 096.19 3 107.23 Net change In working capital (3,660.16) (34.43) (1,004.49) Cash generated from operations 1,390.43 3,820.56 7,736.31 Income taxes refund received net 1324.71} 94.22 1711.121 Net cash aeneraled from ooeratina acllvlfles A 1 065.72 3 914.78 7 025.19
Page 11
STRIDES PHARMA SCIENCE LIMITED 8 Strides CIN: L24230MH 1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashl, Navl Mumbai - 400 703 Corp. Office: "Strides House", Bllekahalll, Bannerghalla Road, Bangalore-560 076. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30 2026 CONSOLIDATED STATEMENT OF CASH FLOW Rs. In MIiiion SI. Particulars For the half year For the previous half For the previous year No. ended year ended ended September 30, 2026 September 30, 2025 March 31, 2026 UNAUDITED UNAUDITED AUDITED B. Cash flow from Investing activities Capital expenditure for properly, plant and equipment and intangible assets, including capital advance 12,664.51) 11.491.91) 14,179.35) Proceeds from sale of properly, plant and equipment and intangible assets 4.57 31.67 63.90 Proceeds from sale of investment properly [net of expenses) 0.19 - 1,128.70 Receipl/[Refund) of advance for sale of investment properly - ISO.DO) ISO.DO) Purchase of long-term investments including investment in associates - - 112.60) Consideration paid towards acquisition of non-controlling interest in subsidiary and business combinations, net of cash acquired 116.52) - 1217.74) Proceeds from sale of investments in mutual funds - 10.26 921.67 Proceeds from loss of control in subsidiary 750.00 - - Deferred consideration received from sale of business - - 513.69 Deferred consideration settled with trade payables - - 106.45 [Investment) / proceeds in fixed deposits with maturity of more than 3 months, net 67.66 19.60) 163.54) Rental income from investment properly 3.83 11.06 12.69 Interest and dividends received lnel of tax on dividend! 31.96 19.91 45.77 Net cash utlllsed In lnvestlna activities B '1,822.82 (1,478.611 '1,730.36 C. Cash flow from financing activities Proceeds from issue of equity shares - 3.87 3.86 Proceeds from Share application money pending allotment 4.25 - Proceeds from long-term borrowings 827.82 574.99 1,705.00 Repayment of long-term borrowings 1333.22) 1481.79) 1919.37) Net decrease in U.S revolver facility 1439.54) 11 ,208.06) 11 ,600.50) Net increase / [decrease) in working capital and short-term borrowings 1,643.56 242.77 [1,308.01) Lease payments (Principal) 1148.73) 1132.67) 1272.99) Lease payments [Interest) 135.04) 148.11) 194.12) Dividends paid 1460.87) 1368.65) 1368.65) Interest oaid on borrowinas 1805.961 1908.691 11 679.311 Net cash generated/(ullhsed)ln financing acflvlfles C 252.27 (2,326.34) (4,534.09)
Page 12
STRIDES PHARMA SCIENCE LIMITED 8 Strides CIN: L24230MH 1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashl, Navl Mumbai - 400 703 Corp. Office: "Strides House", Bllekahalll , Bannerghalla Road, Bangalore-560 076. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30 2026 CONSOLIDATED STATEMENT OF CASH FLOW Rs. In MIiiion SI. Particulars For the half year For the previous half For the previous year No. ended year ended ended September 30, 2026 September 30, 2025 March 31, 2026 UNAUDITED UNAUDITED AUDITED Net lncrease/(decrease) In cash and cash equivalents during the year (A+B+C) (504.83) 109.83 760.74 Cash and cash equivalents at the beginning of the year 1,886.96 1,125.64 1,125.64 Effect of exchange difference s on restatement of foreign currency cash and cash equivalents (8.36) (3.39) 0.58 Cash and cash eauivalents Dursuant to loss of control in a subsidiarv 10.42) - - Cash and cash eaulvalenls at the end ot the period/yea,. 1,373.35 1,232.08 1,886.96 • Comprises : Cash on hand 3.14 3.92 4.64 Balance wlfh banks: - In current accounts 1,074.42 1,059.10 1,659.84 - In deposit accounts 40.56 50.18 51.87 - Funds-in-transit 255.23 118.88 170.61 Total 1,373.35 1,232.08 1,886.96
Page 13
8 Strides STRIDES PHARMA SCIENCE LIMITED CIN: L24230MH1990PLC057062 Regd. Office : Cyber One, Unit No. 902, Plot No - 4 & 6, Sector JOA, Vashl, Navl Mumbai - 400 703 Corp. Office : "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Noles: 1 These consolidated financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2 The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 29, 2026. The statutory auditor has carried out a limited review of the above results and issued unmodified opinion. 3 Based on the "management approach " as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker ("CODM") evaluates the Group 's performance based on an analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and expenditure in individual segments. The CODM evaluates the business, including resource allocation and performance assessment as a single segment, i.e. "Pharmaceutical 11 • Consequently , the Company has only one reportable segment and accordingly disclosures made in these results al the Group level suffice for compliance with the requirements of Ind AS 108. Pharmaceutical segment represents the business of development , manufacture and commercialization of pharmaceutical products other than biological drugs. 4 Excepflonal Items : Rs. In MIilon Particulars 3 Months Preceding 3 Months Corresponding 3 Year lo dale figures Year lo dale figures Previous year ended ended Months ended In the for the period for the previous ended September 30, 2026 June 30, 2026 previous year ended period ended March 31, 2026 September 30, 2025 September 30, 2026 September 30, 2025 UNAUDITED UNAUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED - Expenses related lo product recall and settlements (Refer note 6) (17.04} fl 10.10) (86.34) (127.14) (168.51) (228.79) - Impairment and write down of assets - - 0.03 - 0.01 (34.70) - Business combination and restructurina exoenses (Refer note 51 - 742.07 11.411 742.07 12.89\ 14.94\ Total 117.041 631.97 187.721 614.93 1171.391 /268 .431 5 On March 19, 2025, the Board of Directors of the Company approved the demerger of the Life Sciences and Digital Innovation capabilities business of Arco Lab Private Limited ("Arco Lab"), a subsidiary of the Company, into Pivot Path Private Limited ("Pivot Path"), subsidiary of Arco Lab, pursuant lo a Scheme of Arrangement under Sections 230 lo 232 of the Companies Act, 2013. The Scheme, approved by the Board of Directors of Arco Lab on May 15, 2025, with an appointed date of April 10, 2025, was approved by the Hon'ble National Company Law Tribunal (NCLT) on June 1 2026. In the previous quarter, the Board of Directors of the Compan y, approved the dilution of the Group 's controlling stake in Pivot Path to incoming investors for an aggregate consideration of tl,000 million . Upon completion of the transaction, the Group's shareholding in Pivot Path reduced lo 19.95%, resulting in a loss of control over Pivot Path and the recognition of the retained interest as an investment in associate at fair value as on the date of loss of control. As parf of the transaction, the Company entered into a five-year Master Services Agreement with Pivot Path containing minimum revenue commitment and annual price escalation arrangement . The Group recognized a net gain of U42.07 million on the transaction, including the fair value remeasurement of its retained interest in Pivot Path, which has been disclosed as an exceptional item in these financial results. 6 On March 31 , 2020, US Food and Drug Administration (USFDA or the Agency) issued letters lo all manufacturers of Ranitidine across dosage forms requesting withdrawal of all prescriplion(Rx) and over-the-counter (OTC) ranilidine drugs from the market immediately. This step was based on their ongoing investigation of the N-Nilrosodimeth ylamine (NDMA) impurity in ranitidine medications. As a result. effective April 1, 2020, the Group had ceased further distribution of the product and the recall process is completed. During the year ended March 31, 2022, USFDA issued a letter to the Group lo test for the presence of Azide impurity(s) in Losarfan. The Azide impurities are API process impurity(s), with the API supplier also receiving a similar letter from USFDA. The results confirmed the presence of Azide impurity(s) in the batches tested. As a result, the Group recalled specific batches which had the Azide impurity(s) . During the quarter and half ended September 30, 2026, and previous year ended March 31, 2026, w ith respect lo the above mentioned recalls, the Group is carrying sufficient provision for sales return and has recorded an amount of Rs. 13.52 million, Rs. 27.84 million and Rs. 54.17 million respectively, towards other expenses related lo its product withdrawal and settlements . Furthermore, the expenses recorded also include legal fees incurred by the Group in respect of its ongoing litigations with respect to these recalled products . These amounts, in line with earlier periods, have been recorded as an expense within Exceptional items in the statement of profit and loss during the period. During the year ended March 31, 2025, the Group voluntarily initialed recall of testosterone due lo the presence of trace amounts of Benzene and during the previous year ended March 31, 2026, the Group has successfully relaunched the Product to ensure conformance w ith the FDA's updated requirements . The Group had received certain complaints w hich are legal in nature and are under evaluation. Accordingly the Group has created a provision of Rs. 3.52 million, Rs. 99.30 million and Rs.174.62 million towards the recall and other related expense which has been presented in exceptional items in the Statement of profit and loss during the quarter and half ended September 30, 2026, and previous year ended March 31, 2026 respectively, in line with earlier periods .
Page 14
8 STRIDES PHARMA SCIENCE LIMITED Strides CIN: L24230MH1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No • 4 & 6, Sector 30A. Vashl, Navl Mumbai • 400 703 Corp . Office : "Strides House", Bilekahalli , Banne rghatta Road , Bangalore -560 076. STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30 2026 7 During the previous year ended March 31 . 2026. the Compan y sold its investment property consisting of land and building for a consideration of Rs. l . 128.70 million and recorded a profit of Rs. 1 .021.43 million as other income and the corresponding tax impact is considered as part of tax expense in the statement of profit and loss. 8 Information on Standalone Results : • Rs. In MOllon Particulars 3 Months Preceding 3 Months Corresponding 3 Year to date figures Year to date figures Previous year ended ended Months ended In the tor the period tor the previous ended September 30, 2026 June 30, 2026 previous year ended period ended March 31 , 2026 September 30, 2025 September 30, 2026 September 30, 2025 UNAUDITED UNAUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED Total Income from continuing operations 6,612.89 5,841.23 5,362.44 12,454.12 10,366.18 23,031.98 Profit/ (loss) before tax from continuing operations 172.30 847.58 253.88 1,019.88 417.91 2,031.01 Profit/ (loss) otter tax from continuing operations 92.63 729.28 320.40 821.91 453.87 1,836.35 9 The Board of Direct or.;, al its meeting held on May 18, 2026. recommended a final dividend of ~5 per equi ty share. Follow ing appro val by the share holder.; al the Annual General Meeting , the dividend payment resulted in a c ash outflo w o f appro ximatel y ~461 million during the quarter . For and on behalf of the Board KOMANDUR Digitally signed by KOMANDUR BADREE BADREE Date: 2026 .10.29 t 7:08:19 +05'30' Badree Komandur Bangalore, October 29, 2026 Managing Director and Group CEO
Page 15
B S R & Co. LLP Chartered Accountants Embassy Golf Links Business Park Pebble Beach, B Block, 3rd Floor No. 13/2, off Intermediate Ring Road Bengaluru - 560 071, India Telephone: +91 80 4682 3000 Fax: +91 80 4682 3999 Registered Office: B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 1 Limited Review Report on unaudited standalone financial results of Strides Pharma Science Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Strides Pharma Science Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Strides Pharma Science Limited (hereinafter referred to as “the Company”) for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 (“the Statement”). 2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For B S R & Co. LLP Chartered Accountants Firm’s Registration No.:101248W/W-100022 G Prakash Partner Bangalore Membership No.: 099696 29 October 2026 UDIN:26099696PVYJJJ6265 G Digitally signed byG PRAKASH PRAKASH Date:2026.10.29 17:22:10 +05'30'
Page 16
Rs. in Million Sl. No. Particulars 3 Months ended September 30, 2026 Preceding 3 Months ended June 30, 2026 Corresponding 3 Months ended in the previous year September 30, 2025 Year to date figures for the current period ended September 30, 2026 Year to date figures for the previous period ended September 30, 2025 Previous year ended March 31, 2026 UNAUDITED UNAUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED (1) (2) (3) (4) (5) (6) Continuing Operations Income I Revenue from operations 6,599.07 5,826.48 5,221.52 12,425.55 10,207.68 21,801.35 II Other income(Refer note 4) 13.82 14.75 140.92 28.57 158.50 1,230.63 III Total income (I + II) 6,612.89 5,841.23 5,362.44 12,454.12 10,366.18 23,031.98 IV Expenses (a) Cost of materials consumed 3,032.09 3,091.06 2,556.60 6,123.15 4,666.37 10,195.97 (b) Purchases of stock-in-trade 445.36 509.51 300.07 954.87 457.55 793.96 (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 170.24 (557.85) (36.45) (387.61) 118.16 110.22 (d) Employee benefits expense 1,079.22 1,024.01 964.88 2,103.23 1,905.28 3,816.02 (e) Finance costs 277.64 285.09 294.13 562.73 598.61 1,137.68 (f) Depreciation and amortisation expense 278.06 257.28 215.14 535.34 436.52 912.38 (g) Other expenses 1,157.98 1,148.56 814.19 2,306.54 1,765.78 4,034.74 Total expenses (IV) 6,440.59 5,757.66 5,108.56 12,198.25 9,948.27 21,000.97 V Profit before exceptional items and tax (III - IV) 172.30 83.57 253.88 255.87 417.91 2,031.01 VI Exceptional item(Refer note 5) - 764.01 - 764.01 - - VII Profit before tax (V + VI) 172.30 847.58 253.88 1,019.88 417.91 2,031.01 VIII Tax expense/(benefit) - Current tax 50.89 147.73 (113.69) 198.62 (114.16) 169.95 - Deferred tax 28.78 (29.43) 47.17 (0.65) 78.20 24.71 Total tax expense/(benefit) (VIII) 79.67 118.30 (66.52) 197.97 (35.96) 194.66 IX Profit for the period/year (VII - VIII) 92.63 729.28 320.40 821.91 453.87 1,836.35 STRIDES PHARMA SCIENCE LIMITED CIN: L24230MH1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703. Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 8 Strides
Page 17
STRIDES PHARMA SCIENCE LIMITED 8 Strides CIN: l24230MH1990PLC057062 Regd . Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703. Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Rs, In MIiiion SI. Partlculars 3Monlhs Preceding Corresponding 3 Year lo dale figures Year lo dale figures Previous year No, ended 3Monlhs Months ended In the tor the c urrenl tor the previous ended September 30, 2026 ended previous year period ended period ended March 31, 2026 June 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 UNAUDITED UNAUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED (1l {2) {3) {4) {5) {6) X Other comprehensive Income A Ii) Items that will not be reclassified lo statement of profit and loss - - - - - 46.48 Iii) Income tax relalinQ lo items that will not be reclassified lo statement of profit and loss - - - - - (37,88) B Ii) Items that may be reclassified lo statement of profit and loss 150.86 310.78 (301.87) 461.64 (395.44) (776.28) (ii) Income tax relating to items that may be reclassified to statement ot profit and loss (37,97) (78.22) 105.48 (116.19) 138,18 200,81 Total other comprehensive (loss)/ Income, net of tax for the period/year (X) 112.89 232.56 {196.39) 345.45 {257.26) {566.87) XI Total comprehensive Income for the period/year (IX+ X) 205.52 961.84 124.01 1,167.36 196.61 1,269.48 Earnings per equity share (face value of Rs. 10/- each) (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) (al Basic (Rs.) 1.00 7.91 3.48 8.92 4.92 19.92 (bl Diluted (Rs.) 1.00 7.91 3.48 8.92 4.92 19.92 See accompanying notes lo the Standalone Results
Page 18
Rs. in Million Particulars As at September 30, 2026 As at March 31, 2026 UNAUDITED AUDITED A ASSETS I Non-current assets (a) Property, plant and equipment 6,059.14 6,058.48 (b) Capital work in progress 1,229.36 839.88 (c) Right of Use Assets 215.93 283.52 (d) Goodwill 1,155.77 1,155.77 (e) Other intangible assets 788.72 350.50 (f) Intangibles assets under development 712.52 973.12 (g) Financial assets (i) Investments 18,620.03 18,682.83 (ii) Other financial assets 393.66 354.15 (h) Deferred tax assets (net) 1,025.04 1,140.57 (i) Income tax assets (net) 57.49 155.72 (j) Other non-current assets 296.44 226.73 Total non-current assets 30,554.10 30,221.27 II Current assets (a) Inventories 7,016.09 5,802.70 (b) Financial assets (i) Trade receivables 16,957.72 15,212.83 (ii) Cash and cash equivalents 227.74 161.71 (iii) Other balances with banks 91.86 245.10 (iv) Loans 74.63 72.57 (v) Other financial assets 666.23 319.70 (c) Other current assets 2,575.03 1,921.31 Total current assets 27,609.30 23,735.92 Total assets 58,163.40 53,957.19 CIN: L24230MH1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703. Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 STANDALONE BALANCE SHEET STRIDES PHARMA SCIENCE LIMITED 8 Strides
Page 19
Rs. in Million Particulars As at September 30, 2026 As at March 31, 2026 UNAUDITED AUDITED B EQUITY AND LIABILITIES I Equity (a) Equity Share capital 921.73 921.73 (b) Other equity 32,625.08 31,913.45 Total Equity 33,546.81 32,835.18 II Liabilities 1 Non-current liabilities (a) Financial liabilities (i) Borrowings 2,244.78 1,732.50 (ii) Lease liabilities 159.70 182.45 (iii) Other financial liabilities 304.34 264.32 (b) Provisions 531.47 542.00 Total Non-current liabilities 3,240.29 2,721.27 2 Current liabilities (a) Financial liabilities (i) Borrowings 11,867.14 9,748.92 (ii) Lease liabilities 125.12 178.54 (iii) Trade payables (a) total outstanding dues of micro enterprises and small enterprises and 815.69 430.22 (b) total outstanding dues of creditors other than micro enterprises and small enterprises 7,069.12 6,425.68 (iv) Other financial liabilities 875.33 1,252.13 (b) Current tax liabilities 75.94 - (c) Other current liabilities 302.18 142.34 (d) Provisions 245.78 222.91 Total current liabilities 21,376.30 18,400.74 Total liabilities 24,616.59 21,122.01 Total equity and liabilities 58,163.40 53,957.19 STRIDES PHARMA SCIENCE LIMITED CIN: L24230MH1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703. Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 STANDALONE BALANCE SHEET 8 Strides
Page 20
Rs. In Million For the half year ended September 30, 2026 For the half year ended September 30, 2025 For the year ended March 31, 2026 UNAUDITED UNAUDITED AUDITED A. Cash flow from operating activities Profit before tax Continuing operations 1,019.88 417.91 2,031.01 1,019.88 417.91 2,031.01 Adjustments for: - Depreciation and amortisation expense 535.34 436.52 912.38 1.84 (0.42) (1,027.65) - Provision for impairment of non current investments - - 23.13 - Share based compensation expense 0.88 1.68 3.14 - Finance costs 562.73 598.61 1,137.68 - Interest income (24.68) (141.29) (159.84) - Rental income (0.36) (8.76) (9.50) - Loss allowance on trade receivables (55.00) (5.00) 25.00 - Write off of advances to related party - - 86.74 - Movement in inventory obsolescence 316.66 - (87.60) - Gain on writing off of ROU asset and liability - (2.65) (25.94) - Gain on sale of investment in subsidiary (764.01) - - - Net unrealised exchange (gain)/ loss (284.17) (391.27) (421.96) Operating profit before working capital changes 1,309.11 905.33 2,486.59 Changes in working capital: (Increase)/ Decrease in trade and other receivables (2,142.49) 288.64 (269.80) Increase in inventories (1,530.08) (1,386.31) (1,397.97) Increase/ (Decrease) in trade and other payables 1,204.23 1,253.68 1,972.60 Net change in working capital (2,468.34) 156.01 304.83 Cash generated from operations (1,159.23) 1,061.34 2,791.42 Income taxes (paid)/ refund, net (14.02) 216.01 (12.97) Net cash flow (utilised)/ generated from operating activities A (1,173.25) 1,277.35 2,778.45 STANDALONE STATEMENT OF CASH FLOWS - (Gain)/ Loss on sale/write off of property, plant and equipment, Investment Property and other intangible assets (net) STRIDES PHARMA SCIENCE LIMITED CIN: L24230MH1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703. FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF STANDALONE UNAUDITED RESULTS Sl. No. Particulars 8 Strides
Page 21
Rs. In Million STANDALONE STATEMENT OF CASH FLOWS STRIDES PHARMA SCIENCE LIMITED CIN: L24230MH1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703. FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF STANDALONE UNAUDITED RESULTS For the half year ended September 30, 2026 For the half year ended September 30, 2025 For the year ended March 31, 2026 UNAUDITED UNAUDITED AUDITED B. Cash flow from investing activities (1,124.69) (704.58) (1,635.71) Proceeds from sale of property, plant and equipment and intangible assets 0.92 2.50 16.08 Proceeds from sale of investment property (net) - - 1,128.70 Refund of proceeds for sale of assets - (50.00) - Investments in subsidiaries and others - - (229.08) (Advance refunded)/ Advance received for sale of investment property - - (50.00) Proceeds from sale of investment in subsidiary 750.00 - - Interest received (net of taxes) 8.71 0.81 0.81 Dividend received - 84.94 84.94 Rental income from investment property 0.36 8.76 9.50 Investment in fixed deposits with maturity of more than 3 months, net 70.25 - (15.95) Net cash flow utilised in investing activities B (294.45) (657.57) (690.71) Acquisition for property, plant and equipment and intangible assets, including capital advance and capital creditors Sl. No. Particulars 8 Strides I
Page 22
Rs. In Million STANDALONE STATEMENT OF CASH FLOWS STRIDES PHARMA SCIENCE LIMITED CIN: L24230MH1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703. FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF STANDALONE UNAUDITED RESULTS For the half year ended September 30, 2026 For the half year ended September 30, 2025 For the year ended March 31, 2026 UNAUDITED UNAUDITED AUDITED C. Cash flow from financing activities Proceeds from issue of equity shares - 3.87 3.86 Proceeds from share application money pending allotment 4.25 - - Proceeds from long-term borrowings 801.25 574.79 1,065.57 Repayment of long-term borrowings (261.50) (423.21) (794.62) Proceeds/(Repayment) from short-term borrowings 2,088.36 287.28 (625.72) Dividends paid (460.87) (368.65) (368.65) Lease payments (76.18) (65.30) (133.90) Interest on Lease liability paid (17.68) (22.81) (44.93) Interest paid on borrowings (543.89) (580.49) (1,090.92) Net cash flow generated/(utilised) in financing activities C 1,533.74 (594.52) (1,989.31) Net increase/ (decrease) in cash and cash equivalents during the year (A+B+C) 66.04 25.26 98.43 Cash and cash equivalents at the beginning of the year 161.71 63.28 63.28 Cash and cash equivalents at the end of the year* 227.75 88.54 161.71 * Comprises: Cash on hand 2.36 2.15 2.10 Balance with banks: - In current accounts 10.94 10.85 10.94 - Funds-in-transit 214.45 75.54 148.67 Total 227.75 88.54 161.71 Sl. No. Particulars 8 Strides I I I I
Page 23
1 2 3 4 5 6 Bangalore, 29 October 2026 For and on behalf of the Board During the previous year ended March 31,2026, the Company sold its investment property consisting of land and building for a consideration of Rs.1,128.70 million and recorded a profit of Rs.1,021.43 million as other income and the corresponding tax impact is considered as part of tax expense in the statement of profit and loss. Badree Komandur Managing Director and Group CEO On March 19, 2025, the Board of Directors of the Company approved the demerger of the Life Sciences and Digital Innovation capabilities business ofArco Lab Private Limited ("Arco Lab"), a subsidiary of the Company, into Pivot Path Private Limited ("Pivot Path"), a subsidiary of Arco Lab, pursuant to a Scheme of Arrangement under Sections 230 to 232 ofthe Companies Act, 2013. The Scheme, approved by the Board of Directors of Arco Lab on May 15, 2025, with an appointed date of April 10, 2025, was approved bythe Hon'ble National Company Law Tribunal (NCLT) on May 18 2026 and the scheme was made effective pursuant to ROC filings effective June 1, 2026. In the previous quarter, the Board of Directors of the Company approved the dilution of the Company's stake in Pivot Path to incoming investors for an aggregate consideration of1,000 million. Upon completion of the transaction on June 30, 2026 , the Group's shareholding in Pivot Path reduced to 19.95% and the Group ceased tohave control over Pivot Path. The transaction also included as a condition precedent, on the execution ofa five-year Master Services Agreement with Pivot Path containing minimum revenue commitment and annual price escalation arrangement. Accordingly, the Company recognized a net gain of 764.01 million, which has been disclosed as an exceptional item in these financial results. Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker ("CODM") evaluates the Company's performance based onan analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and expenditure inindividual segments. The CODM evaluates the business, including resource allocation and performance assessment as a single segment, i.e. The Company publishes standalone and consolidated financial results. Pursuant to Paragraph 4 of Ind AS 108, Operating Segments, the segment information has been disclosed in the consolidated financial results. Accordingly,no separate segment information is presented in these standalone financial results. Pharmaceutical segment represents the business of development, manufacture and commercialization of pharmaceutical products other than biological drugs. The Board of Directors, at its meeting held on May 18, 2026, recommended a final dividend of 5 per equity share. Following approval by the shareholders at the Annual General Meeting, the dividend payment resulted in a cash outflow of approximately 461 million during the quarter. STRIDES PHARMA SCIENCE LIMITED CIN: L24230MH1990PLC057062 Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703. Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076. STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 Notes: These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 29, 2026.The statutory auditor has carried out a limited review of the above results for the quarter and half year ended September 30, 2026 and has issued an unmodified opinion. 8 Strides "Pharmaceutical" . KOMANDUR BADREE Digitally signed by KOMANDUR BADREE Date: 2026.10.29 17:02:56 +05'30'